Five Dartmouth staff and faculty were included on this year’s New Hampshire 200, an annual list produced by New Hampshire Business Review of influential business leaders across major industries in the state. They were honored at an event in Manchester on Dec. 9.
Recognized by the bi-monthly business newspaper were:
Joanne Conroy ’77, CEO and president of Dartmouth-Hitchcock Health, was recognized as a leader in health care. “Leaders should always be learners and active listeners,” said Conroy, who oversees the state’s only academic health system and its largest private employer. A physician, Conroy is a professor of anesthesiology at the Geisel School of medicine.
Jamie Coughlin, director of the Magnuson Center for Entrepreneurship at Dartmouth, was recognized in the education category. “I am honored to receive this prestigious recognition for the second time, but this recognition is really a testament to the amazing team, supporters and partners that have made this dream of building a world class entrepreneurial program at Dartmouth a reality,” he said. “What is so exciting about my work is the impact we have had and will have on generations of students and faculty who are building new ventures that will touch the world.”
Professor of Engineering Tillman Gerngross was recognized in the technology sector. Gerngross, who also has an adjunct appointment in biological sciences, is the co-founder and CEO of the biotech company Adimab and a founder or co-founder of a number of other companies, including GlycoFi, Arsanis, Amagma Therapeutics, and Adagio Therapeutics.
Also recognized in technology were Phil Ferneau ’84, Tuck ’96, and Jake Reder. Ferneau, an adjunct professor of business administration at the Tuck School of Business, is managing partner and co-founder of Borealis Ventures, a venture capital firm in Hanover. He was the founding executive director of the Center for Private Equity and Venture Capital at Tuck. Reder, CEO of Celdara Medical, is director of the New Ventures Office at Geisel. Celdara works to build academic and early-stage innovations into high-potential medical companies.
